{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:05:19Z","timestamp":1789477519264,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,10,5]]},"DOI":"10.1038\/s41416-026-03513-y","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:44:10Z","timestamp":1782211450000},"page":"1019-1021","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Front-line chemo-immunotherapy for advanced penile cancer: ready for prime time?"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1534-5397","authenticated-orcid":false,"given":"Zachariah","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Pettaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-2206","authenticated-orcid":false,"given":"Omar","family":"Alhalabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9821-8662","authenticated-orcid":false,"given":"Andrew C.","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"3513_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00345-008-0310-z","volume":"27","author":"LC Pagliaro","year":"2009","unstructured":"Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009;27:221\u20135. https:\/\/doi.org\/10.1007\/s00345-008-0310-z.","journal-title":"World J Urol"},{"key":"3513_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1200\/JCO.2024.42.4_suppl.9","volume":"42","author":"K Gullapalli","year":"2024","unstructured":"Gullapalli K, Ionescu F, Roman Souza G, Paravathaneni M, Eschrich SA, Kim Y, et al. Alterations in tumor immune microenvironment and progressive immune exhaustion with advancing penile squamous cell carcinoma using multiplex immunofluorescence and image analysis. J Clin Oncol. 2024;42:9\u20139. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.9.","journal-title":"J Clin Oncol"},{"key":"3513_CR3","doi-asserted-by":"crossref","unstructured":"Jacob JM, Ferry EK, Gay LM, Elvin JA, Vergilio J-A, Ramkissoon S, et al. Comparative genomic profiling of refractory and metastatic penile and nonpenile cutaneous squamous cell carcinoma: implications for selection of systemic therapy. J Urol. 2019;201:541\u20138.","DOI":"10.1016\/j.juro.2018.09.056"},{"key":"3513_CR4","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","volume":"28","author":"LC Pagliaro","year":"2010","unstructured":"Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010;28:3851\u20137. https:\/\/doi.org\/10.1200\/JCO.2010.29.5477.","journal-title":"J Clin Oncol"},{"key":"3513_CR5","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2202170.","journal-title":"N Engl J Med"},{"key":"3513_CR6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR, et al. Neoadjuvant\u2013adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388:813\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2211437.","journal-title":"N Engl J Med"},{"key":"3513_CR7","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Penile Cancer (Version 2.2026, February 2026). Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/penile.pdf [Accessed June 19, 2026]."},{"key":"3513_CR8","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jamaoncol.2025.3266","volume":"11","author":"F Cotait Maluf","year":"2025","unstructured":"Cotait Maluf F, Trindade K, Preto D, de Almeida Luz M, Medeiros Milhomem Beato P, Assed Bastos D, et al. Pembrolizumab plus platinum-based chemotherapy for patients with advanced penile cancer: the nonrandomized HERCULES (LACOG 0218) clinical trial. JAMA Oncol. 2025;11:1314\u201320. https:\/\/doi.org\/10.1001\/jamaoncol.2025.3266.","journal-title":"JAMA Oncol"},{"key":"3513_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.euo.2024.04.021","volume":"8","author":"X Garc\u00eda Del Muro","year":"2025","unstructured":"Garc\u00eda Del Muro X, P\u00e1ez L\u00f3pez-Bravo D, Cu\u00e9llar-Rivas MA, Maroto P, Giannatempo P, Castellano D, et al. Retifanlimab in advanced penile squamous cell carcinoma: the phase 2 ORPHEUS study. Eur Urol Oncol. 2025;8:278\u201386. https:\/\/doi.org\/10.1016\/j.euo.2024.04.021.","journal-title":"Eur Urol Oncol"},{"key":"3513_CR10","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1200\/JCO.22.02894","volume":"41","author":"HM de Vries","year":"2023","unstructured":"de Vries HM, Rafael TS, Gil-Jimenez A, de Feijter JM, Bekers E, van der Laan E, et al. Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis (the PERICLES study): a phase II trial. J Clin Oncol. 2023;41:4872\u201380. https:\/\/doi.org\/10.1200\/JCO.22.02894.","journal-title":"J Clin Oncol"},{"key":"3513_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1200\/JCO.2025.43.5_suppl.9","volume":"43","author":"A Challapalli","year":"2025","unstructured":"Challapalli A, Bahl A, Venugopal B, Afshar M, Alifrangis C, Thomson A, et al. EPIC-B: phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma. J Clin Oncol. 2025;43:9\u20139. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.9.","journal-title":"J Clin Oncol"},{"key":"3513_CR12","doi-asserted-by":"publisher","first-page":"S720","DOI":"10.1016\/j.annonc.2021.08.111","volume":"32","author":"D Pouessel","year":"2021","unstructured":"Pouessel D, Beylot-Barry M, Esma SB, Pontville MD, Coquan E, Mahammedi H, et al. 715P Nivolumab in pretreated metastatic penile squamous cell carcinoma: results of the penile cohort from the French AcS\u00e9 prospective program. Ann Oncol. 2021;32:S720 https:\/\/doi.org\/10.1016\/j.annonc.2021.08.111.","journal-title":"Ann Oncol"},{"key":"3513_CR13","doi-asserted-by":"publisher","unstructured":"Bahl A, Challapalli A, Venugopal B, Afshar M, Alifrangis C, Thomson A, et al. EPIC-A: phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma. J Clin Oncol. 2025;43:1\u20131. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.1.","DOI":"10.1200\/JCO.2025.43.5_suppl.1"},{"key":"3513_CR14","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.ccell.2025.03.023","volume":"43","author":"X An","year":"2025","unstructured":"An X, Guo SJ, Yan R, Xue T, Xiong LB, Ma HL, et al. Neoadjuvant toripalimab plus nimotuzumab combined with taxol-based chemotherapy in locally advanced penile squamous cell carcinoma. Cancer Cell. 2025;43:970\u2013980.e3. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.023.","journal-title":"Cancer Cell"},{"key":"3513_CR15","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41416-025-03321-w","volume":"134","author":"X Shan","year":"2026","unstructured":"Shan X, Bai H, Ning H, Xie C, Chen Y, Xing S, et al. Efficacy and safety of tislelizumab combined with chemotherapy for locally advanced penile cancer: a prospective, single-arm clinical study. Br J Cancer. 2026;134:764\u201371. https:\/\/doi.org\/10.1038\/s41416-025-03321-w.","journal-title":"Br J Cancer"},{"key":"3513_CR16","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375\u201391. https:\/\/doi.org\/10.1093\/annonc\/mdv383.","journal-title":"Ann Oncol"},{"key":"3513_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0305-7372(93)90010-O","volume":"19","author":"R Pazdur","year":"1993","unstructured":"Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel (Taxol\u00ae) and docetaxel (Taxotere\u00ae). Cancer Treat Rev. 1993;19:351\u201386. https:\/\/doi.org\/10.1016\/0305-7372(93)90010-O.","journal-title":"Cancer Treat Rev"},{"key":"3513_CR18","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.urology.2010.03.082","volume":"76","author":"CA Pettaway","year":"2010","unstructured":"Pettaway CA, Pagliaro L, Theodore C, Haas G. Treatment of visceral, unresectable, or bulky\/unresectable regional metastases of penile cancer. Urology. 2010;76:S58\u201365. https:\/\/doi.org\/10.1016\/j.urology.2010.03.082.","journal-title":"Urology"},{"key":"3513_CR19","doi-asserted-by":"publisher","first-page":"TPS5108","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5108","volume":"42","author":"LC Pagliaro","year":"2024","unstructured":"Pagliaro LC, Moore CN, Tan W, Bobek O, Hillman DW, Gupta S, et al. A phase II trial of enfortumab vedotin for locally advanced and metastatic squamous cell carcinoma of the penis. J Clin Oncol. 2024;42:TPS5108\u2013TPS5108. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS5108.","journal-title":"J Clin Oncol"},{"key":"3513_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2022.12.008","volume":"49","author":"GD Grass","year":"2023","unstructured":"Grass GD, Chahoud J, Lopez A, Dhillon J, Eschrich SA, Johnstone PAS, et al. An analysis of nectin-4 (PVRL4) in penile squamous cell carcinoma. Eur Urol Open Sci. 2023;49:1\u20135. https:\/\/doi.org\/10.1016\/j.euros.2022.12.008.","journal-title":"Eur Urol Open Sci"},{"key":"3513_CR21","doi-asserted-by":"publisher","first-page":"TPS7","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS7","volume":"40","author":"CA Pettaway","year":"2022","unstructured":"Pettaway CA, Nicholson S, Spiess PE, Pagliaro LC, Watkin N, Barber J, et al. The international penile advanced cancer trial (InPACT): the first phase III trial for squamous carcinoma of the penis with regional lymph node metastases. J Clin Oncol. 2022;40:TPS7\u2013TPS7. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS7.","journal-title":"J Clin Oncol"},{"key":"3513_CR22","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1080\/14796694.2025.2577632","volume":"21","author":"F Hatoum","year":"2025","unstructured":"Hatoum F, Souza GR, Johnson J, Miller J, Fazili A, Pettaway CA, et al. Phase 2 study of dostarlimab plus niraparib in stage III-IV recurrent or refractory Penile squamous cell carcinoma. Future Oncol. 2025;21:3619\u201327. https:\/\/doi.org\/10.1080\/14796694.2025.2577632.","journal-title":"Future Oncol"},{"key":"3513_CR23","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/jnci\/djad155","volume":"115","author":"T El Zarif","year":"2023","unstructured":"El Zarif T, Nassar AH, Pond GR, Zhuang TZ, Master V, Nazha B, et al. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. JNCI J Natl Cancer Inst. 2023;115:1605\u201315. https:\/\/doi.org\/10.1093\/jnci\/djad155.","journal-title":"JNCI J Natl Cancer Inst"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03513-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03513-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03513-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:13:53Z","timestamp":1789474433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03513-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10,5]]}},"alternative-id":["3513"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03513-y","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ZT and ACJ have no competing interest. CAP reports- Editorial Consultant: UpToDate Penile Cancer online Series- Wolters Kluwer Publisher. OA reports Scientific advisory board fees from Seagen, Silverback Therapeutics, Adaptimmune, Bicycle Therapeutics, AstraZeneca and Cardinal Health; Educational program speaker from Curio Science and Aptitude Health; Research funding to the institution from AstraZeneca, Ikena Oncology, Genentech, Rondo Therapeutics and Arcus Biosciences. MTC reports Consulting\/Advisory Roles: Eisai, Exelixis, Merck, Pfizer; Trials with Institutional Grant Support: Exelixis, Pfizer, AstraZeneca; Non-branded educational programs: Curio Science, Dava Oncology, MJH LifeSciences.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}